Combination Therapy for EGFR-Mutated Lung Cancer

被引：14
作者：
Wu, Yi-Long [1 ]
Zhou, Qing [1 ]
机构：
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Guangzhou, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 21期
关键词：
OSIMERTINIB;
D O I：
10.1056/NEJMe2311559
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Targeted therapy has improved prognoses for patients with advanced non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),(1) and a second trial, AURA3, showed that resistance mutations could be detected and then targeted with osimertinib.(2) FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 months.(3,4) Osimertinib became the standard therapy for advanced NSCLC with EGFR-sensitive mutations. The story . . .
引用
收藏
页码：2005 / 2007
页数：3
相关论文
共 50 条
[41]   Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy [J].
Llinas-Quintero, Nestor ;
Gonzalez-Hoyos, David ;
Yepes, Andres ;
Herrera, Diego A. ;
Pelaez-Arroyave, Sebastian ;
Caicedo-Zamudio, Carlos ;
Blanco-Daza, Erick ;
Cuello-Lopez, Javier .
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
[42]   Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer [J].
Ku, Li-Jung Elizabeth ;
Tsai, Jui-Hung ;
Chen, Li-Jun ;
Yang, Szu-Chun .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
[43]   Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? [J].
Milano, Michael T. ;
Salama, Joseph K. ;
Chmura, Steven J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (06) :605-607
[44]   Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? [J].
Patel, Shruti R. ;
Neal, Joel W. .
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) :1631-1635
[45]   Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer [J].
Calvo, Emiliano ;
Lee, Jong-Seok ;
Kim, Sang-We ;
Moreno, Victor ;
deCastro Carpeno, Javier ;
Weilert, Doris ;
Laus, Gianluca ;
Mann, Helen ;
Vishwanathan, Karthick .
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08) :1099-1109
[46]   A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer [J].
Hsu, Robert ;
Benjamin, David J. .
FRONTIERS IN ONCOLOGY, 2023, 13
[47]   Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis [J].
Yu, Zhuchen ;
Xu, Fei ;
Zou, Juntao .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) :505-517
[48]   Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy [J].
Zhong, Hua ;
Zhang, Xueyan ;
Tian, Panwen ;
Chu, Tianqing ;
Guo, Qisen ;
Yu, Xinmin ;
Yu, Zhuang ;
Li, Yalun ;
Chen, Lijuan ;
Liu, Jie ;
Zhang, Yan ;
Guan, Yan ;
Shi, Xun ;
Wang, Jing ;
Zhao, Yanqiu ;
Han, Baohui .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
[49]   Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report [J].
Aubanel, Marjorie ;
Swalduz, Aurelie ;
Avrillon, Virginie ;
Doublet, Louis ;
Mastroianni, Benedicte ;
Neidhardt-Berard, Eve-Marie ;
Perol, Maurice .
CLINICAL LUNG CANCER, 2020, 21 (06) :E601-E606
[50]   Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer [J].
Haratake, Naoki ;
Misumi, Toshihiro ;
Yamanaka, Takeharu ;
Seto, Takashi .
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04)
12345